177Lu-DOTA0-Tyr3-Octreotate
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for 177Lu-DOTA0-Tyr3-Octreotate, covering 2017-10-02 to 2021-03-16. Get the full timeline:
Most recent: Clinical Trial Update: Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer [Phase 1, Phase 2]